![]() |
|
|
Forward to a colleague |
||
Access Full Stories Biogen Idec has announced it is seeking a buyer for the company and has already received several expressions of interest - including a reputed $23bn (€16.2bn) bid from billionaire corporate raider Carl Icahn... Read The death of PCR for sequencing amplification? Two new techniques have been developed that could signal the end of PCR (polymerase chain reaction) amplification for sequencing applications and dramatically increase the efficiency of sample preparation... Read GSK's disdain is blatant over new rules for patent GlaxoSmithkline (GSK) has expressed its disdain for looming changes to drug patent application rules in the US and has launched a lawsuit to try and stop them coming into force next month... Read Improved infrastructure key to cheaper drugs Improving the technology infrastructure of drug development could save the industry hundreds of millions of dollars, according to a new US government study, with the ultimate winners being patients... Read Negative credit ratings puts US pharma in glum Moody Moody's Investors Service believes that things are set to get worse for the US pharma industry and has revised is credit ratings outlook from stable to negative... Read |
||||||||||||||||||
All News Headlines for: October | September | August |
||||||||||||||||||
Manufacturing Variations in Polysorbate Batches Lot to lot variances in a series of Polysorbate preparations was easily and clearly differentiated and identified by utilizing charged aerosol detection (CAD), a new universal detectorfor HPLC... Click Here | ||||||||||||||||||
|
Related Industry News Paving the way to next generation biologics As biologic drugs become ever more prominent, Avecia Biologics is winning plaudits for its advanced protein expression system pAVEway, gaining recognition from international industry experts and investing to meet... Read Indian firm takes over German biologics plant An Indian firm has taken over the contract biologics manufacturing business of German corporation Siegfried... Read Moss protein factories scaled up Normally, they are green, sort of spongy and found in dank nooks and crannies - but mosses have now been designed as therapeutic protein producing factories and are being implemented on a grand scale... Read Crucell up on MedImmune deal Following the shaky moment Crucell experienced last month after the failure of Merck's HIV drug, share prices had a healthy boost this morning on the news that MedImmune will be collaborating with the Dutch firm... Read
|
||||||||||||||||||
|
|||||
Forward to a colleague |
|||||
To continue to receive this newsletter in your inbox, please add newsletter@DrugResearcher.com to your address book |
||
Update preferences | Change your email address | Unsubscribe |
||
Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback |
||
| © 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com |
||